Citigroup’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-39,742
| Closed | -$396K | – | 6204 |
|
|
2025
Q2 | $396K | Buy |
39,742
+20,558
| +107% | +$166K | ﹤0.01% | 3759 |
|
|
2025
Q1 | $115K | Sell |
19,184
-834,597
| -98% | -$6.13M | ﹤0.01% | 4520 |
|
|
2024
Q4 | $6.56M | Buy |
853,781
+833,589
| +4,128% | +$7.16M | ﹤0.01% | 1707 |
|
|
2024
Q3 | $206K | Buy |
20,192
+8,497
| +73% | +$130K | ﹤0.01% | 4327 |
|
|
2024
Q2 | $174K | Sell |
11,695
-284,289
| -96% | -$4.07M | ﹤0.01% | 3964 |
|
|
2024
Q1 | $4.04M | Sell |
295,984
-48,818
| -14% | -$532K | ﹤0.01% | 1874 |
|
|
2023
Q4 | $3.78M | Buy |
344,802
+258,468
| +299% | +$2.56M | ﹤0.01% | 1782 |
|
|
2023
Q3 | $945K | Sell |
86,334
-148,333
| -63% | -$1.9M | ﹤0.01% | 2567 |
|
|
2023
Q2 | $3.11M | Sell |
234,667
-54,218
| -19% | -$773K | ﹤0.01% | 1833 |
|
|
2023
Q1 | $3.93M | Buy |
288,885
+54,589
| +23% | +$978K | ﹤0.01% | 1624 |
|
|
2022
Q4 | $4.58M | Sell |
234,296
-59,957
| -20% | -$1.17M | ﹤0.01% | 1516 |
|
|
2022
Q3 | $5.61M | Buy |
294,253
+168,551
| +134% | +$3.88M | ﹤0.01% | 1485 |
|
|
2022
Q2 | $2.59M | Buy |
125,702
+93,349
| +289% | +$2.22M | ﹤0.01% | 1928 |
|
|
2022
Q1 | $1.04M | Sell |
32,353
-176,147
| -84% | -$6.4M | ﹤0.01% | 2923 |
|
|
2021
Q4 | $9.71M | Sell |
208,500
-204,972
| -50% | -$6.82M | 0.01% | 1398 |
|
|
2021
Q3 | $11.2M | Sell |
413,472
-19,012
| -4% | -$497K | 0.01% | 1338 |
|
|
2021
Q2 | $11.1M | Buy |
432,484
+397,181
| +1,125% | +$9.46M | 0.01% | 1350 |
|
|
2021
Q1 | $1.21M | Buy |
35,303
+31,999
| +968% | +$1.16M | ﹤0.01% | 2844 |
|
|
2020
Q4 | $112K | Buy |
3,304
+2,791
| +544% | +$73.9K | ﹤0.01% | 5448 |
|
|
2020
Q3 | $13K | Buy |
+513
| New | +$13.8K | ﹤0.01% | 6450 |
|
Other funds holding ITOS
Citigroup's ITOS Position: Q3 2025 in Review
Citigroup sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 39,742 shares — an estimated $396K sold.
Citigroup first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $11.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Citigroup reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 39,742 iTeos Therapeutics shares in Q3 2025, an estimated $396K.
- Citigroup first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Citigroup's iTeos Therapeutics position peaked at $11.2M in Q3 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.